Cabbacis Granted U.S. Patent for Vaporizer Pods
NIAGARA FALLS, N.Y. — Cabbacis (OTCQB: CABI), a U.S. federally-licensed tobacco-product manufacturer focused on harm-reduction products being developed under the iBlend™ brand name, today announced that the United States Patent and Trademark Office has issued a patent to Cabbacis for vaporizer pods for oral electronic vaporizers.
Article content
Article content
U.S. Patent No. 12,349,724, which expires on July 27, 2038, includes ten claims on pods for electronic vaporizers. The claims cover vaporizer pods comprising blends of at least 5 mg of conventional-nicotine reconstituted tobacco and at least 5 mg of hemp, and separately, at least 5 mg of reduced-nicotine reconstituted tobacco and at least 5 mg of hemp. Reconstituted tobacco is typically used in closed-end electronic vaporizer pods. Commercial examples of popular, closed-end electronic vaporizers – also known as heat-not-burn products – include IQOS®, Ploom® and glo®.
Article content
Vaporizer pods covered under the 724 patent that contain conventional-nicotine tobacco and hemp will provide consumers with pleasant and differentiated taste and sensory characteristics, as compared to the above vaporizer brands that contain conventional-nicotine tobacco without any hemp.
Article content
Cabbacis owns two other previously-issued U.S. patents on vaporizer pods containing tobacco and hemp: 10,777,091 and 10,973,255 along with various international vaporizer pod patents.
Article content
The Company's patented, reduced-nicotine, iBlend™ vaporizer pods and patented, reduced-nicotine, iBlend™ cigarettes in development are to assist vapers or smokers of conventional tobacco products to vape or smoke less or transition to less harmful tobacco or nicotine products. iBlend™ reduced-nicotine cigarettes contain approximately 95 percent less nicotine than conventional cigarette brands. The Company's products in development are patented in many of the largest tobacco markets across the globe including the United States, China, Europe, Brazil and Japan.
Article content
Joseph Pandolfino, Chief Executive Officer of Cabbacis, commented, 'We are thrilled to announce this new patent for vaporizer pods, further fortifying our already robust intellectual property position. This patent, when taken in tandem with our existing patents, comprehensively cover, across more than 30 countries, any ratio of reduced-nicotine tobacco and hemp blended together in cigarettes and/or any ratio of conventional-nicotine tobacco and hemp or reduced-nicotine tobacco and hemp blended together in vaporizer products.'
Article content
About Cabbacis
Article content
Cabbacis (OTCQB: CABI) is committed to commercializing groundbreaking tobacco harm-reduction products in the global tobacco market for the world's one billion smokers with its flagship iBlend™ reduced-nicotine cigarettes and vaporizer pods in development. These patent protected products combine reduced-nicotine tobacco with non-intoxicating hemp to assist in vaping or smoking less, transitioning to less harmful tobacco products, and/or increasing quit attempts. Both types of products in development are predominately tobacco and include hemp. In a recent clinical trial, the Company's patented, reduced-nicotine iBlend™ cigarettes were highly rated for satisfaction on the standardized mCEQ questionnaire and significantly reduced cravings for usual brand cigarettes. The Company also plans to commercialize reduced-nicotine tobacco cigarettes and little cigars without hemp and vaporizer pods with conventional-nicotine tobacco and hemp.
Article content
The worldwide patent portfolio of Cabbacis LLC includes 35 issued patents and various pending patent applications across the United States, Europe, China, India, Japan, Indonesia, Russia, South Korea, Canada, Australia, New Zealand, Mexico, Brazil and other countries – where approximately two-thirds of the world's smokers reside. Cabbacis holds 7 U.S. patents. Cabbacis LLC is a wholly-owned subsidiary of Cabbacis Inc.
Article content
Reduced-nicotine cigarettes without hemp that contain about 95 percent less nicotine than conventional cigarettes have been evaluated in dozens of independent studies. Results demonstrate, as reviewed in Donny and White 2022 (Int J Drug Policy 99:103436), that subjects smoked fewer cigarettes per day, reduced their nicotine dependence and exposure, doubled their quit attempts, and/or increased their number of smoke-free days.
Article content
Cautionary Note Regarding Forward-Looking Statements
Article content
This press release includes forward-looking statements within the meaning of the federal securities law. All statements other than statements of historical or current facts made in this document are forward-looking. We identify forward-looking statements in this document by using words or phrases such as 'anticipate,' 'believe,' 'consider,' 'continue,' 'could,' 'estimate,' 'expect,' 'foresee,' 'intend,' 'likely,' 'may,' 'objective,' 'potential,' 'plan,' 'predict,' 'project,' 'seek,' 'should,' 'will' and similar words or phrases and their negatives. Forward-looking statements reflect our current expectations and are inherently uncertain. Actual outcomes or results could differ materially for a variety of reasons. Factors that could cause actual results to differ materially are described in 'Risk Factors' in our Regulation A Offering Circular filed with the SEC and in our Annual Report on Form 1-K for the period ended December 31, 2024 filed with the SEC. We undertake no responsibility to publicly update or revise any forward-looking statement except as required by applicable law.
Article content
This press release does not constitute an offer to sell or the solicitation of an offer to buy the Company's securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to qualification or registration under the securities laws of that state or jurisdiction.
Article content
Article content
Article content
Article content
Article content
Contacts
Article content
Investor Relations Contact:
Article content
Article content
Lucas A. Zimmerman
Article content
Article content
Managing Director
Article content
Article content
Article content
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
National Post
16 minutes ago
- National Post
Invest in Precision: Mitutoyo America Corporation Announces Limited-Time Savings on MiSTAR 555 and 575 Coordinate Measuring Machines
Article content Sorry, your browser doesn't support embedded videos. Article content AURORA, Ill. — In today's unpredictable economy, one investment still delivers lasting certainty: Precision is the smartest investment. For a limited time, Mitutoyo America Corporation, the trusted leader in advanced metrology solutions, is offering a rare opportunity to invest in the future success of your inspection capabilities with exclusive promotional pricing of up to 26 percent off the MiSTAR 555 and 575 CMM through September 30, 2025. Article content Article content 'The MiSTAR CMM is built to thrive on the shop floor. It is rugged, reliable and fully adaptable to your machining process. With this exclusive promotion, you're not just getting precision, you're getting value with savings of up to 26 percent.' Article content Mitutoyo's MCOSMOS software scales to meet your inspection needs, from basic measurement and reporting with MCOSMOS-1, to CAD model part programming with free-form surface evaluation MCOSMOS-2 and MCOSMOS-3 adds scanning of 2D line and 3D surface profiles with CAD model analysis. Article content Three configurations offered: Article content BASIC model type- PH6 TP20 probing and MCOSMOS-1 software for small shops with essential digital routines Advanced model type- PH6M SP25 probe and MCOSMOS-2 software for growing operations who require CAD model part programming with free-form surface evaluation. Ultimate model type- PH10 SP25 MCOSMOS-3 software for high-throughput environments Article content The Mitutoyo MiSTAR CMM delivers reliable performance across a broad range of operating environments with guaranteed accuracy from 10 °C to 40 °C, and enhanced capability within narrower ranges of 10 °C to 30 °C and 18 °C to 22 °C. Article content Each MiSTAR configuration is delivered ready for immediate operation and includes: Article content When accuracy matters, manufacturers turn to Mitutoyo for proven performance that drives quality forward. Contact your local Mitutoyo representative or distributor to schedule a demo, consultation, or get a quote. Article content At Article content , precision is our profession. We are the leader in metrology instruments, solutions and support, offering more than 5,500 products, the largest and most comprehensive product portfolio of any commercial metrology provider. Mitutoyo also has the highest-performing A2LA-accredited calibration laboratories (A2LA Certificate No. 0750.01) in the nation. For more information, contact the Mitutoyo inside sales team at Article content Article content Article content Article content Article content Contacts
CTV News
16 minutes ago
- CTV News
Weight loss medications like Ozempic linked to eating disorders in boys and men: study
Prescription weight loss medication use has been linked to significantly higher rates of eating disorders in adolescent boys and men, according to a new study. Led by Kyle Ganson, an assistant professor at the University of Toronto's faculty of social work, the study focuses on an often overlooked population and raises new concerns about the use of high-profile medications like Ozempic and Wegovy for weight loss. 'While these medications are typically prescribed for diabetes or obesity, their off-label use for weight loss has become popular,' Ganson said in a news release from the University of Toronto. 'Our findings underscore potential psychological implications for young men.' The study analyzed survey data from 1,543 boys and men from Canada and the U.S. who were between the ages of 15 and 35. While only 1.2 per cent of the sample reported using prescription weight loss medication in the past 12 months, they were much more likely to report eating disorder attitudes and behaviours than others, such as loss of control while eating (63.2 per cent versus 36.2 per cent), binge eating (63.2 per cent versus 34.1 per cent) and purging via vomiting (15.8 per cent versus 5.6 per cent). The study also found that boys and men who used the medication were typically older, had a higher body mass index, and were more likely to identify as not being white or heterosexual. 'Boys and men are frequently left out of the conversation about eating disorders and body image pressures, but this study makes clear that they are not immune to the risks,' Ganson said. The study was published earlier this month in the journal Eating Behaviors. 'There is a greater need to describe the prevalence of use among understudied populations, as well as identify associations with eating disorder attitudes and behaviours,' the study explained. 'Health and mental health care professionals should be cognizant of the associations found in this study to ensure proper eating disorder assessment and intervention are provided to individuals, including boys and men, who use prescription weight loss medication.'
CTV News
16 minutes ago
- CTV News
Morgan Stanley stays bullish on U.S. stocks
In this Oct. 18, 2011, file photo, the Morgan Stanley logo is displayed on its Times Square building, in New York. (AP Photo/Mark Lennihan, File) Morgan Stanley backed its bullish stance on U.S. equities on Monday, citing strong earnings momentum, and said it was expecting a modest pullback in the third quarter that could create an opportunity to buy the dip. The Wall Street brokerage is leaning more towards its bull case of the benchmark S&P 500 hitting 7,200 points by the middle of the year, it wrote in a note. In May, the brokerage said the S&P 500 was expected to hit 6,500 in the second quarter of 2026. 'With earnings on solid footing into next year and the Fed closer to cutting rates, valuations can remain supported around current levels (~22x) as we think about the 12-month outlook,' Morgan Stanley equity strategists led by Michael Wilson said. However, the brokerage said rising Treasury yields - especially the 10-year note US10YT=RR breaching above 4.5% - could increase rate sensitivity for equities and an underperformance of rate-sensitive stocks such as small caps. Morgan Stanley also expects tariff-related cost pressures to show up later this year, which could impact company margins and bump up inflation, leading to a change in rate cut expectations by the Federal Reserve. Lastly, it estimates that seasonal trends may hit stocks in from mid-July through August. However, the brokerage said it would buy the dips as the risks could be temporary and only lead to a mild consolidation. Jefferies also raised its S&P 500 year-end target to 5,600 from its previous forecast of 5,300, according to the brokerage's note published on Friday. (Reporting by Shashwat Chauhan in Bengaluru; Editing by Anil D'Silva)
